CORMEDIX INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
CORMEDIX INC. (CRMD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.00% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-05-29.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2019-05-29
- CORMEDIX INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was 0.00%.
- CORMEDIX INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was 0.00%.
- CORMEDIX INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was 0.00%, a 100.00% decline from fiscal 2015.
- CORMEDIX INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2015 was 3.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2018-12-31 | 0.00% 10-K · filed 2019-05-29 |
| 2017-12-31 | 0.00% 10-K · filed 2019-05-29 |
| 2016-12-31 | 0.00% 10-K · filed 2018-03-19 |
| 2015-12-31 | 3.20% 10-K · filed 2017-03-16 |
| 2014-12-31 | 0.00% 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |